SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2022 / Cilt: 28 - Sayı: 1

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Ibrahim A. ABDELAZIM
Mohannad ABU-FAZA
Soud M. AL-AJMI
Osama O. AMER
Svetlana SHIKANOVA
Bakyt KARIMOVA
Pages
1–6
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy.
📊
Key Findings & Data:STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group.
💡
Conclusion & Impact:CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

🔖

Cite This Article

ABDELAZIM, I. A., ABU-FAZA, M., AL-AJMI, S. M., AMER, O. O., SHIKANOVA, S., KARIMOVA, B. (2022). Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 28 - Sayı: 1, 1–6. https://ajindex.com/articles/525798

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Api O, Breyman C, Cetiner M, Demir C, Ecder T. Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report. Turk J Obstet Gynecol. 2015;12(3):173-81. Doi: 10.4274/tjod.01700
  2. World Health Organization. Iron and Folate Supp - lementation: Standards for Maternal and Neonatal Care. Integrated Management of Pregnancy and Childbirth (IMPAC). Department of Making Pregnancy Safer. WHO; 2007
  3. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72(1 Suppl):257S-264S. Doi: 10.1093/ajcn/72.1.257S 4. Froessler B, Gajic T, Dekker G, Hodyl NA. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet. 2018;298(1):75-82. Doi: 10.1007/s00404-018- 4782-9
  4. Roberts CL. Nippita TA. International caesarean section rates: the rising tide. Lancet Glob Health. 2015;3(5):e241– e242. Doi: 10.1016/S2214-109X (15)70111-7 6. Patterson JA, Roberts CL, Isbister JP. Irving DO. Nicholl MC. Morris JM. et al. What factors contribute to hospital variation in obstetric transfusion rates? Vox Sang. 2015;108(1):37-45. Doi: 10.1111/vox.12186 7. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016;264(1):41-6. Doi: 10.1097/SLA.0000000000001646 8. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific opinion on the safety of heme iron (blood peptonates) for the proposed uses as a source of iron added for nutritional purposes to foods for the general population, including food supplements. EFSA J. 2010;8(4):1585. Doi: 10.2903/j.efsa.2010. 1585
  5. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. British Committee for Standards in Haematology. UK Guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156(5):588- 600. Doi: 10.1111/j.1365-2141.2011.09012.x 10. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011;4(3):177-84. Doi: 10. 1177/1756283X11398736
  6. Abdelazim IA, Abu-Faza M, Elbiaa AAM, Othman HS, Alsharif DA, Elsawah WF. Heme iron polypeptide (Proferrin®-ES) versus iron saccharate complex (Ferrosac) for treatment of iron deficiency anemia during pregnancy. Acta Med Int.